In first, Salk scientists use sound waves to control brain cells

(Press-News.org) LA JOLLA--Salk scientists have developed a new way to selectively activate brain, heart, muscle and other cells using ultrasonic waves. The new technique, dubbed sonogenetics, has some similarities to the burgeoning use of light to activate cells in order to better understand the brain.

This new method--which uses the same type of waves used in medical sonograms--may have advantages over the light-based approach--known as optogenetics--particularly when it comes to adapting the technology to human therapeutics. It was described September 15, 2015 in the journal Nature Communications.

"Light-based techniques are great for some uses and I think we're going to continue to see developments on that front," says Sreekanth Chalasani, an assistant professor in Salk's Molecular Neurobiology Laboratory and senior author of the study. "But this is a new, additional tool to manipulate neurons and other cells in the body."

In optogenetics, researchers add light-sensitive channel proteins to neurons they wish to study. By shining a focused laser on the cells, they can selectively open these channels, either activating or silencing the target neurons. But using an optogenetics approach on cells deep in the brain is difficult: typically, researchers have to perform surgery to implant a fiber optic cable that can reach the cells. Plus, light is scattered by the brain and by other tissues in the body.

Chalasani and his group decided to see if they could develop an approach that instead relied on ultrasound waves for the activation. "In contrast to light, low-frequency ultrasound can travel through the body without any scattering," he says. "This could be a big advantage when you want to stimulate a region deep in the brain without affecting other regions," adds Stuart Ibsen, a postdoctoral fellow in the Chalasani lab and first author of the new work.

Chalasani and his colleagues first showed that, in the nematode Caenorhabditis elegans, microbubbles of gas outside of the worm were necessary to amplify the low-intensity ultrasound waves. "The microbubbles grow and shrink in tune with the ultrasound pressure waves," Ibsen says. "These oscillations can then propagate noninvasively into the worm."

Next, they found a membrane ion channel, TRP-4, which can respond to these waves. When mechanical deformations from the ultrasound hitting gas bubbles propagate into the worm, they cause TRP-4 channels to open up and activate the cell. Armed with that knowledge, the team tried adding the TRP-4 channel to neurons that don't normally have it. With this approach, they successfully activated neurons that don't usually react to ultrasound.

So far, sonogenetics has only been applied to C. elegans neurons. But TRP-4 could be added to any calcium-sensitive cell type in any organism including humans, Chalasani says. Then, microbubbles could be injected into the bloodstream, and distributed throughout the body--an approach already used in some human imaging techniques. Ultrasound could then noninvasively reach any tissue of interest, including the brain, be amplified by the microbubbles, and activate the cells of interest through TRP-4. And many cells in the human body, he points out, can respond to the influxes of calcium caused by TRP-4.

"The real prize will be to see whether this could work in a mammalian brain," Chalasani says. His group has already begun testing the approach in mice. "When we make the leap into therapies for humans, I think we have a better shot with noninvasive sonogenetics approaches than with optogenetics."

Both optogenetics and sonogenetics approaches, he adds, hold promise in basic research by letting scientists study the effect of cell activation. And they also may be useful in therapeutics through the activation of cells affected by disease. However, for either technique to be used in humans, researchers first need to develop safe ways to deliver the light or ultrasound-sensitive channels to target cells.

INFORMATION:

Other researchers on the study were Stuart Ibsen and Ada Tong of the Salk Institute, and Carolyn Schutt and Sadik Esener of the University of California, San Diego.

The work and the researchers involved were supported by a Salk Institute Pioneer Fund Postdoctoral Fellowship, a Salk Institute Innovation Grant, the Rita Allen Foundation, the W.M. Keck Foundation and the National Institutes of Health.

About the Salk Institute for Biological Studies: The Salk Institute for Biological Studies is one of the world's preeminent basic research institutions, where internationally renowned faculty probes fundamental life science questions in a unique, collaborative and creative environment. Focused both on discovery and on mentoring future generations of researchers, Salk scientists make groundbreaking contributions to our understanding of cancer, aging, Alzheimer's, diabetes and infectious diseases by studying neuroscience, genetics, cell and plant biology and related disciplines.

Faculty achievements have been recognized with numerous honors, including Nobel Prizes and memberships in the National Academy of Sciences. Founded in 1960 by polio vaccine pioneer Jonas Salk, MD, the Institute is an independent nonprofit organization and architectural landmark.